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Parity, oral contraceptive use, and hysterectomy are known to protect against ovarian cancer, whereas the effect
of other reproductive factors remains unclear. The authors investigated the association between several repro-
ductive and hormonal factors and the risk of epithelial invasive ovarian cancer among postmenopausal women
participating in the Netherlands Cohort Study on Diet and Cancer. Information on reproductive history and exog-
enous hormone use was obtained through a self-administered questionnaire at baseline in 1986. After 16.3 years
of follow-up, 375 cases and 2,331 subcohort members were available for case-cohort analysis. Ovarian cancer risk
was reduced for parous women, with increasing parity, and for hysterectomized women. Moreover, the authors
found evidence that oral contraceptive use is protective against ovarian cancer, even when initiated at an older
age. In addition, a reduced risk was observed for each year reduction in age at natural menopause and per year
reduction in total menstrual life span. A small increased risk was observed with prolonged time to pregnancy, but no
difference was found between ever-married nulliparous women and never-married nulliparous women. Moreover,
no associations were observed for age at ﬁrst birth, age at menarche, age at ﬁrst and last use of oral contracep-
tives, and use of hormone replacement therapy.
hormones; infertility; ovarian neoplasms; prospective studies; reproductive history
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; HRT, hormone replacement therapy; OC, oral contraceptive.
Ovarian cancer is the ﬁfth most common cancer among
women in Europe (1). Unknown pathogenesis and late di-
agnosis contribute to poor survival. Different reproductive
and hormonal factors have been studied to clarify their in-
ﬂuence on ovarian carcinogenesis. Epidemiologic studies
consistently show a protective effect of parity, oral contra-
ceptive (OC) use, and hysterectomy (2–22). Less clear are
the effects of age at ﬁrst birth and timing of OC use. More-
over, results for other reproductive risk factors, such as age
at menarche, age at menopause, and hormone replacement
therapy (HRT), remain conﬂicting.
The increased risk for nulliparous women could, in part,
reﬂect an association between ovarian cancer and subfertility.
Generally, no strong overall associations have been found
between subfertility and ovarian cancer (23–29). However,
an increased risk has been observed in some studies for sub-
fertilewomenwhoremainedchildless(20,21,23,25,26,28).
Most studies that examined reproductive and hormonal
factors used a case-control design, which may suffer from
recall and selection bias. Moreover, interpretation of results
has been hampered by inadequate control for potential con-
founding factors, small sample sizes, and differences in ref-
erence groups used. We conducted a large prospective study
among postmenopausal women within the Netherlands Co-
hort Study on Diet and Cancer to examine the association of
fertility and of reproductive and hormonal factors with the
risk of epithelial ovarian cancer.
MATERIALS AND METHODS
The cohort
The prospective Netherlands Cohort Study on Diet and
Cancer started in September 1986 with the enrollment of
1181 Am J Epidemiol 2010;172:1181–1189participants aged 55–69 years (30). In total, 62,573 women
were included, who were all presumed to be postmeno-
pausal. For efﬁciency reasons, data processing and analysis
were based on the case-cohort approach. Cases were derived
from the entire cohort, and number of person-years at risk
for the entire cohort was estimated from a subcohort of
2,589 women randomly sampled from the total cohort at
baseline. The subcohort has been contacted by letter every
2 years regarding migration and vital status. In case of no
response, the municipal population registries were con-
tacted. No women were lost to follow-up. For more details
on the Netherlands Cohort Study on Diet and Cancer, refer
to the article by van den Brandt et al. (30). After exclusionof
women with prevalent malignancy at baseline (other than
nonmelanoma skin cancer) and women who, at baseline,
reported they had undergone an oophorectomy, 2,406
female subcohort members remained available.
The study protocol of the Netherlands Cohort Study on
Diet and Cancer was approved by the medical ethics com-
mittees of the University Hospital Maastricht in February
1985 and TNO Nutrition and Food Research in July 1986.
Identiﬁcation of cases
Incident cancer cases were identiﬁed by computerized
record linkage of the entire cohort to the Netherlands Cancer
Registry and the Netherlands Pathology Registry (30, 31).
The completeness of cancer follow-up was estimated to
be more than 95% (32). During a follow-up period of
16.3 years, 394 microscopically conﬁrmed cases of invasive
epithelial ovarian cancer were identiﬁed. Women with in-
complete covariate data (i.e., parity (parous/nulliparous,
number of children) and OC use (never/ever)) were ex-
cluded, leaving 375 cases and 2,331 subcohort members
for analysis.
Questionnaire data
The baseline questionnaire included self-reported infor-
mation on year of ﬁrst marriage, number of children, year of
ﬁrst birth, age at menarche, age at menopause, and how
menopause was induced. Participants were asked whether
they had ever used OCs (yes/no), at which age they started
and stopped using OCs, and the total duration of use (in
years). In addition, they were asked whether they had ever
used HRT and in which year they started and stopped using
it. In an open question, participants were asked which types
of surgery they had undergone. This item enabled us to de-
ﬁne whether women had undergone oophorectomy or hys-
terectomy, or a combination of both. For women reporting
a hysterectomy, age at menopause could be misclassiﬁed
because many of these women reported that their meno-
pause started on the date of the surgery. Therefore, we
restricted our analysis of age at menopause to women expe-
riencing a natural menopause.
Reductions in years of menstrual life span were estimated
using different indicators, according to the studies of Dossus
et al. (33) and Pelucchi et al. (34). We estimated the inﬂu-
ence on ovarian cancer for each year that menarche
is delayed; for each year menopause is advanced in time
(entering age at natural menopause into the model with
a minus sign); per year of being pregnant (calculated as
number of children 3 0.75); per year of OC use; per year
reduction in time between menarche and menopause; and
per year reduction in total menstrual life span. The latter was
estimated by calculating the time between age at menarche
and age at natural menopause and subsequently subtracting
years of pregnancy and years of OC use. Time to pregnancy
was deﬁned as the time between marriage and ﬁrst birth. To
analyze time to pregnancy, we excluded women who used
OCs prior to the birth of their ﬁrst child (n ¼ 5).
Data analysis
Person-years at risk were calculated from the start of the
study until ovarian cancer diagnosis, death, emigration, or
end of follow-up (December 31, 2002). The association be-
tween various reproductive and hormonal factors and risk
of ovarian cancer was evaluated in age-adjusted and multi-
variate case-cohort analyses using Cox proportional hazards
models. Standard errors were estimated using the robust
Huber-White sandwich estimator to account for additional
variance introduced by sampling from the cohort. This
method is equivalent to the variance-covariance estimator
presented by Barlow (35).
Analyses were adjusted a priori for age, parity (number of
children), and OC use (ever/never) because of their estab-
lished inﬂuence on ovarian cancer development. We consid-
ered other potential confounders based on evidence from
epidemiologic literature, including height (cm), body mass
index (kg/m
2), family history of ovarian or breast cancer
(yes/no), educational level (primary school, lower voca-
tional school, high school/intermediate vocational school,
higher vocational school/university), nonoccupational phys-
ical activity ( 30 minutes/day, 31–60 minutes/day, 61–90
minutes/day, >90 minutes/day), smoking status (never, cur-
rent, former), and all other reproductive and hormonal fac-
tors under study. Confounding was evaluated starting with
a full multivariate model and using a backward elimination
approach (36). If eliminating a covariate from the full Cox
regression model changed the hazard ratio by 10% or more,
the covariate was considered a confounder and was retained
in the model. Otherwise, that covariate was dropped from
the multivariate model. None of the potential confounders
met this criterion. Therefore, all models were adjusted for
only age, parity, and OC use. Moreover, ages at ﬁrst and last
use of OC and HRT were additionally adjusted for duration
of use of OC and HRT, respectively.
We also examined whether results differed by age, parity,
OC use, hysterectomy, family history of ovarian or breast
cancer, body mass index, and smoking status. We used both
stratiﬁed analyses and the likelihood ratio test to compare
proportional hazards regression models with and without the
interaction term (37). The proportional hazards assumption
was tested using the scaled Schoenfeld residuals and with
graphic tests (38). To calculate the P value for the trend test,
we assigned participants the median value of each category
and treated this variable as a continuous term in the model
(36). Two-sided P values are reported throughout the paper
and were considered statistically signiﬁcant if <0.05. All
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package (release 9.1; Stata Corporation, College Station,
Texas).
RESULTS
Baseline characteristics of cases and subcohort members
are presented in Table 1. Compared with subcohort mem-
bers, ovarian cancer cases were slightly taller and heavier,
and they were more likely to be never smokers. Of the
ovarian cancers, 182 were serous invasive (48.5%), 31 were
endometrioid (8.3%), 35 were mucinous (9.3%), and 15
were clear-cell (4.0%). The mean age at diagnosis was
70.4 (standard deviation, 5.9) years.
Table 2 shows the associations betweenvarious reproduc-
tive factors and ovarian cancer risk. Compared with nullip-
arous women, parous women had a lower risk (hazard ratio
(HR) ¼ 0.71, 95% conﬁdence interval (CI): 0.55, 0.93).
Moreover, risk decreased by almost 10% for each additional
livebirth, which showed a statistically signiﬁcant trend (P <
0.001). In addition, ovarian cancer risk was decreased for
women with a history of hysterectomy (HR ¼ 0.50, 95% CI:
0.34, 0.72). Age at ﬁrst birth was not associated with ovarian
cancer risk. Observations were essentially unchanged after
further adjustment for number of full-term pregnancies.
Women who ever used OCs had an almost 30% reduced
ovarian cancer risk compared with those who never used
OCs (HR ¼ 0.71, 95% CI: 0.52, 0.97; Table 3). This ﬁnding
was most pronounced for women who used OCs for more
than 5 years (HR ¼ 0.47, 95% CI: 0.30, 0.76). We observed
no statistically signiﬁcant associations for age at ﬁrst and
last use of OC, ever use of HRT, and age at ﬁrst and last use
of HRT. For duration of HRT use, the proportional hazards
assumption did not hold, and the number of cases in the
predeﬁned intervals subsequently became too small to val-
idly interpret the results. The observed risk estimates re-
mained essentially the same after adjustment for age at
menopause and induced menopause.
We examined the association between ovarian cancer and
different exposures known to reduce menstrual life span,
mutually adjusted for each other (Table 4). For all of the
exposures, except for delay in age at menarche, trends of
decreasing risk with decreasing years of menstrual life span
were found. We observed a lower ovarian cancer risk of 2%
and 5% per year reduction in age at natural menopause and
per year of OC use, respectively, and a 10% risk reduction
per year of being pregnant. Furthermore, we observed a re-
duced risk for each year reduction in time between menar-
che and menopause (HR ¼ 0.98, 95% CI: 0.95, 1.00).
Moreover, we observed a 3% reduction in ovarian cancer
risk for each year that total menstrual life span was reduced
(HR ¼ 0.97, 95% CI: 0.95, 0.99). This association did not
change after exclusion of women whose menopause was
induced.
Ovarian cancer risk increased by 4% per year delay in
conception (HR ¼ 1.04, 95% CI: 0.99, 1.09; Table 5). This
observation remained essentially unchanged after adjust-
ment for total number of children (results not shown). No
difference in ovarian cancer risk was observed between
ever-married nulliparous women and never-married nullip-
arous women (HR ¼ 1.04, 95% CI: 0.65, 1.68; OC users
were excluded).
We found no evidence of effect measure modiﬁcation by
any of the potential effect modiﬁers (results not shown). In
addition, we observed no clear heterogeneity across the se-
rous, endometrioid, and mucinous subtypes. As the number
Table 1. Baseline Characteristics of Cases and Subcohort Members of the Netherlands Cohort
Study on Diet and Cancer, 1986–2002
Cases (n 5 375) Subcohort (n 5 2,331)
Mean (SD) No. % Mean (SD) No. %
Age, years 62.0 (4.3) 61.5 (4.3)
Height, cm 165.8 (6.1) 165.2 (6.2)
Weight, kg 69.7 (10.8) 68.5 (10.2)
Body mass index, kg/m
2 25.2 (3.5) 25.1 (3.5)
Family history of ovarian
or breast cancer
30 8.0 199 8.5
Educational level
Primary school 129 34.9 806 35.0
Lower vocational school 96 26.0 539 23.4
High school/intermediate
vocational school
118 31.9 764 33.2
Higher vocational school/
university
27 7.3 191 8.3
Smoking status
Never 241 64.3 1,361 58.4
Current 67 17.9 491 21.1
Former 67 17.9 479 20.6
Abbreviation: SD, standard deviation.
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dence intervals became relatively wide.
DISCUSSION
In this prospective study, parity, OC use, and hysterec-
tomy substantially reduced epithelial ovarian cancer risk. In
addition, ovarian cancer risk was reduced with earlier age
at menopause, per year of being pregnant, for shorter time
intervals between menarche and menopause, and per year
reduction in total menstrual life span. For pregnancies, the
protective effect was strongest. Furthermore, we observed
an increased ovarian cancer risk by increasing time to
pregnancy.
We need to underscore some population characteristics
that make this cohort unique but must be kept in mind when
interpreting the results. In our cohort, birth rates were high,
with a median of 3 and a range of 0–15. Only 24.1% of these
women reported ever use of OCs. In addition, women
started usingOCs at a relatively late age: a mean of 40 years.
All women were postmenopausal, and the mean age of par-
ticipants at baselinewas 62 years. Therefore, results may not
be generalizable to premenopausal women.
The major strengths of our study include its prospective
design, with detailed exposure and covariate assessment
prior to diagnosis. Subjects were followed for up to 16.3
years, with a nearly complete follow-up.
A potential source of bias is possible underreporting of
oophorectomies by hysterectomized women. Because ex-
cluding hysterectomized women did not alter the results,
this factor is unlikely to have substantially affected our re-
sults. In addition, recall of reproductivefactors and surgeries
by women aged 55–69 years could lead to some misclassi-
ﬁcation. Pregnancies are expected to be recalled accurately
regardless of age; however, other reproductive and hor-
monal factors are likely to be recalled less accurately.
Exposure and covariate information was assessed indepen-
dently of the outcome; therefore, misclassiﬁcation is most
likely undifferential. Another limitation of our study is that
a proxy had to be used for reduced fertility. Although time
to pregnancy is a validated measure of biologic fertility,
wewere not able to directly determine it (39–41). Therefore,
we used time to childbirth after marriage as a surrogate
measure for time to pregnancy. Because birth control mea-
sures were sparse during these women’s reproductive life,
especially in the years between their marriage and their ﬁrst
Table 2. Reproductive Factors in Association With Ovarian Cancer Risk in the Netherlands
Cohort Study on Diet and Cancer, 1986–2002
No. of
Cases
Person-
Years in the
Subcohort
Age Adjusted Multivariate
Adjusted
a
HR 95% CI HR 95% CI
Parity
Nulliparous 88 5,961.0 1.00 Referent 1.00 Referent
Parous 287 28,624.5 0.68 0.53, 0.89 0.71 0.55, 0.93
No. of children
0 88 5,961.0 1.00 Referent 1.00 Referent
1–2 130 10,539.9 0.85 0.63, 1.15 0.88 0.65, 1.19
3–4 108 11,653.7 0.64 0.47, 0.86 0.66 0.49, 0.90
>4 49 6,430.9 0.51 0.35, 0.74 0.53 0.36, 0.78
P for trend
b <0.001 <0.001
Overall trend per
term pregnancy
375 34,585.5 0.90 0.85, 0.95 0.91 0.86, 0.96
Age at ﬁrst birth, years
<20 3 690.4 0.51 0.16, 1.61 0.51 0.15, 1.69
20–24 63 7,331.3 1.00 Referent 1.00 Referent
25–29 152 14,043.6 1.24 0.93, 1.67 1.25 0.91, 1.71
 30 68 6,381.7 1.20 0.85, 1.69 1.21 0.83, 1.75
P for trend
b 0.16 0.15
Overall trend per
year increase
286 28,447.0 1.02 0.99, 1.05 1.02 0.99, 1.05
Hysterectomy
No 342 28,825.2 1.00 Referent 1.00 Referent
Yes 33 5,760.2 0.49 0.34, 0.72 0.50
c 0.34, 0.72
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
a Adjusted for age and oral contraceptive use (ever/never).
b Calculated by using the median for each category and modeled as a continuous variable.
c Additionally adjusted for parity (number of children).
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nancy. For the same reason, nulliparity among married
women might be seen as a valuable proxy for reduced fer-
tility. Nevertheless, results should be interpreted with cau-
tion. Finally, the sample size limited our ability to analyze
data by histologic subtype.
In line with our results, other studies consistently ob-
served a decreased ovarian cancer risk for parous women,
with increasing parity (2, 3, 5, 6, 11, 15, 16, 18, 19, 21, 22),
for OC users, and with increasing duration of OC use (7, 12–
15, 21, 22, 42–44). OCs were introduced in the early 1960s,
when women in our study population were aged 33–47
years. Mean age at ﬁrst OC use was 40 years. Our results
thus imply that OC use is preventive against ovarian cancer,
even when initiated at an older age. The incessant ovulation
hypothesis, proposed by Fathalla (45), postulates that ovar-
ian cancer develops through repeated trauma to the covering
epithelium of the ovary during ovulation.
Recent ﬁndings implicate the fallopian tube ﬁmbria as
a possible site of origin of ovarian carcinomas (46–48). Piek
et al. (49) revisited the incessant ovulation hypothesis and
suggested that incessant ovulation increases ovarian cancer
risk by increasing the risk of inclusion of exfoliated tubal
epithelial cells into the ovarian stroma and by increasing
mitotic activity within tubal epithelium. According to this
hypothesis, parity and OC use reduce ovarian cancer risk by
reducing the lifetime ovulation numbers. Also concordant
with this hypothesis, we observed a clear trend per year
reduction in total menstrual life span. Although we could
estimate menstrual life span only crudely, our observation of
a 3% decrease in risk for each year reduction in total men-
strual life span is consistent with the 2.5%–6% increase
in ovarian cancer risk associated with each ovulation year
observed in other studies (19, 34, 50).
When all factors relating to menstrual life span were
analyzed simultaneously, we found that pregnancies had
Table 3. Exogenous Hormone Use in Association With Ovarian Cancer Risk in the Netherlands
Cohort Study on Diet and Cancer, 1986–2002
No. of
Cases
Person-
Years in the
Subcohort
Age Adjusted Multivariate Adjusted
a
HR 95% CI HR 95% CI
OC use
Never 310 25,916.9 1.00 Referent 1.00 Referent
Ever 65 8,668.6 0.67 0.49, 0.91 0.71 0.52, 0.97
Duration of OC
use, years
Never 310 25,916.9 1.00 Referent 1.00 Referent
 5 32 3,246.6 0.87 0.58, 1.31 0.92 0.61, 1.38
>5 22 4,443.2 0.44 0.28, 0.71 0.47 0.30, 0.76
Age at ﬁrst OC
use, years
 40 31 5,211.8 1.00 Referent 1.00 Referent
>40 32 3,170.7 1.36 0.78, 2.39 1.28
b 0.68, 2.43
Age at last OC
use, years
 45 18 2,910.8 0.91 0.51, 1.60 0.51
b 0.24, 1.10
>45 42 5,282.9 1.00 Referent 1.00 Referent
HRT use
Never 314 28,679.8 1.00 Referent 1.00 Referent
Ever 44 4,175.4 0.97 0.69, 1.36 0.97
c 0.69, 1.37
Age at ﬁrst HRT
use, years
 50 22 2,114.4 1.00 Referent 1.00 Referent
>50 17 1,500.2 1.10 0.56, 2.18 0.96
c 0.47, 1.97
Age at last HRT
use, years
 50 12 1,275.0 1.00 Referent 1.00 Referent
>50 28 2,241.0 1.28 0.61, 2.66 1.39
c 0.63, 3.03
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; HRT, hormone replacement therapy;
OC, oral contraceptive.
a Adjusted for age and parity (number of children).
b Additionally adjusted for duration of OC use.
c Additionally adjusted for duration of HRT use.
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servation, along with the observed protective effect of OCs
initiated at an older age, suggests that development of ovar-
ian cancer is more complex than could be explained by
anovulatory action alone. However, the result regarding re-
ductions in total menstrual life span is limited by the lack
of information on breastfeeding, menstrual patterns, and in-
complete pregnancies. Besides, accurate estimation of men-
strual life span is difﬁcult because menstrual cycles vary
within and between women, and not all menstrual cycles
are ovulatory. Therefore, our association for total menstrual
life span might be underestimated. The World Cancer Re-
search Fund concluded in 2007, based on 1 cohort and 10
case-control studies, that there is only limited evidence sug-
gesting that lactation protects against ovarian cancer (51).
However, 1 cohort and 1 case-control study, published after
the World Cancer Research Fund report, found inverse as-
sociations between total duration of breastfeeding and ovar-
ian cancer (52, 53). Therefore, our observation of a stronger
protective effect of pregnancies compared with other factors
could reﬂect a protective role of breastfeeding.
Excessive stimulation of ovarian tissue by hormones such
as pituitary gonadotropins, estrogens, and androgens is also
suggested to increase ovarian cancer risk (54, 55). Pregnan-
cies and OCs suppress pituitary gonadotropin secretion.
Moreover, OCs reduce endogenous androgen and estrogen
levels. Another mechanism by which parity and OCs might
reduce ovarian cancer risk is by increasing circulating pro-
gesterone levels. Moreover, it has been proposed that preg-
nancies clear malignantly transformed cells from the ovaries
(2). This alternate hypothesis was recently extended to
the cell clearance hypothesis supported by Rostgaard et al.
(56), which is based on the idea that a fraction of the genet-
ically modiﬁed (premalignant) cells are cleared after each
pregnancy.
In line with other studies (4, 8–10, 13, 17, 21), we found
that risk of ovarian cancer was decreased for women with
a history of hysterectomy. According to the androgen hy-
pothesis, hysterectomy might reduce ovarian cancer by re-
ducing testosterone levels (57). It also eliminates or reduces
uterine growth factors involved in ovarian cancer pathogen-
esis (8). Moreover, hysterectomy alters ovarian blood ﬂow
and consequently impairs ovarian function (58–60). Fur-
thermore, hysterectomy may reduce ovarian cancer devel-
opment by blocking access of ovarian carcinogens that enter
the peritoneal cavity via the vagina (4). Recently, a novel
hypothesis regarding the origin of ovarian cancer was pro-
posed by Massuger et al. (61), in which serous ovarian
cancer is hypothesized to originate in the uterus. This hy-
pothesis, if correct, easily explains the protective effect of
hysterectomies.
In contrast with other studies (2, 18, 21, 22, 62), we did
not observe a reduced ovarian cancer risk with increasing
age at ﬁrst birth. A higher age at ﬁrst birth in other studies
could indicate a longer duration of OC use; in our popula-
tion, as stated before, women started using OCs at an older
age.
We observed a decreased ovarian cancer risk per year that
menopause was advanced in time, which is consistent with
most studies (9, 34, 63–66) but contrasts with others (18, 21,
67). Ayounger age at menopause indicates less exposure to
ovulatory cycles and might therefore decrease ovarian can-
cer risk according to the incessant ovulation hypothesis.
Our ﬁnding of a lack of association between age at men-
arche and ovarian cancer risk is in line with most studies
(18, 34, 63, 67, 68), but not all (15, 21). We also did not
observe a clear association of age at ﬁrst and last use of OCs
with ovarian cancer risk, which again is consistent with
most studies (12, 14, 42, 44), but not all (43, 69).
In this study, ever use of HRT was not associated with
ovarian cancer risk. This result agrees with results of
Table 5. Reduced Fertility in Association With Ovarian Cancer Risk
in the Netherlands Cohort Study on Diet and Cancer, 1986–2002
No. of
Cases
Person-
Years in the
Subcohort
HR
a 95% CI
Time to pregnancy
b 282 28,017.8 1.04 0.99, 1.09
Nulliparity among
ever-married
women
c
39 5,961.0 1.04 0.65, 1.68
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
a Adjusted for age.
b Calculated as time between marriage and ﬁrst birth (in years).
c Ever-married women versus never-married women.
Table 4. Reductions in Years of Menstrual Life Span in Association
With Ovarian Cancer Risk in the Netherlands Cohort Study on Diet
and Cancer, 1986–2002
No. of
Cases
Person-
Years in the
Subcohort
HR 95% CI
Risk for each year that
menarche is delayed
313 26,501.9 1.02
a 0.95, 1.09
Risk for each year that
menopause is
advanced in time
b
313 26,501.9 0.98
a 0.95, 1.01
Risk per year of OC use 313 26,501.9 0.95
a 0.91, 0.99
Risk per year of being
pregnant
c 313 26,501.9 0.90
a 0.83, 0.98
Risk per year reduction
in time between
menarche and
menopause
d
349 31,796.0 0.98
e 0.95, 1.00
Risk per year reduction
in total menstrual life
span
f
313 26,501.9 0.97
e 0.95, 0.99
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; OC, oral
contraceptive.
a Mutually adjusted for the other risk factors in the table (except for
year reduction in time between menarche and menopause and year
reduction in total menstrual life span) and for age.
b Age at natural menopause was entered in the model with a minus
sign.
c Calculated as follows: (number of children 3 0.75).
d Calculated as the time interval between menarche and meno-
pause and entered into the model with a minus sign.
e Age adjusted.
f Calculated as follows: (age at natural menopause   age at
menarche   duration of OC use   total years of being pregnant)
and entered into the model with a minus sign.
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Whittemore et al. (21), but it contradicts results from most
studies, including 4 meta-analyses, that found an increased
ovarian cancer risk for ever users of HRT (15, 21, 70–74).
Consistent with the estrogen hypothesis, associations in
these studies were mostly stronger for unopposed estrogen
therapy users (54, 55). Because progestins were added to
HRT in 1985 (75), we assume that almost all HRT pre-
scribed before the start of the Netherlands Cohort Study
on Diet and Cancer consisted of oral estrogen therapy. Most
likely, the group of women who used HRTin our population
was too small to detect associations.
If increased ovarian cancer risk for nulliparous women
stems from difﬁculties in conceiving, ovarian cancer risk
shouldbe higher with prolongedtime to pregnancy and for
nulliparous women who married compared with nullipa-
rous women who never married. Indeed, prolonged time to
pregnancy elevated ovarian cancer risk in our study, which
is consistent with previous studies (20, 21, 25, 26, 28).
However, we did not observe a difference between ever-
married nulliparous women and never-married nullipa-
rous women. This lack of association could be due to
the relatively small number of cases for this particular
analysis. Therefore, we cannot form any reliable conclu-
sion regarding the effect of subfertility on ovarian cancer
risk.
The analysis according to histologic subtype was limited
by the small number of cases in the different strata and
the relatively high number of cases with not-otherwise-
speciﬁed adenocarcinoma (International Classiﬁcation of
Diseases for Oncology code 8140/3). Therefore, we were
unable to observe clear differences between these subtypes.
In conclusion, we observed a reduced ovarian cancer risk
with increasing parity, increasing duration of OC use, hys-
terectomy, younger age at natural menopause, and per year
reduction of total menstrual life span. We provided evidence
that OC use is protective, even when initiated at an older
age. Moreover, we found an increased ovarian cancer risk
with prolonged time to pregnancy. Additional research is
needed to further elucidate the different biologic pathways
of ovarian carcinogenesis.
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